NCT01146028已完成1 期
Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Bioequivalence based on Cmax and AUC parameters
研究概览
简要总结
The purpose of this bioequivalence study is to compare the test Tizanidine Hydrochloride 4mg tablets of Dr.Reddys Laboratories Limited with reference zanaflex® 4mg tablets of Elan in healthy adult subjects under fasting conditions.
详细描述
Randomized, 2-way crossover, bioequivalence study of Tizanidine Hydrochloride 4mg tablets and zanaflex® 4mg tablets administered As 1 x 4mg tablet in healthy adult subjects under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may be done using different media (e.g. radio, newspaper, Anapharm Web site). Subjects must meet all of the following criteria in order to be included in the study:
- •Subjects will be females and/or males, smokers or non-smokers, 18 years of age and older.
- •Female subjects will be post-menopausal or surgically sterilized.
- •Post-menopausal status is defined as absence of menses for the past 12 months.
- •Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at least 6 months ago.
排除标准
- •Subjects to whom any of the following applies will be excluded from the study:
- •Clinically significant abnormalities found during medical screening.
- •Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- •Clinically significant illnesses within 4 weeks of the administration of study medication.
- •History of neuromuscular disease.
- •Abnormal laboratory tests judged clinically significant.
- •ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg, or diastolic blood pressure lower than 70 or over 90; or heart rate less than 60 bpm) at screening.
- •Subjects with BMI ≥ 30.
- •History of allergic reactions to tizanidine hydrochloride.
- •Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical sub investigator, contraindicates the subject's participation in this study.
- •Positive urine drug screen at screening.
- •Positive testing for hepatitis B, hepatitis C or HN at screening.
- •Positive urine pregnancy test at screening.
- •Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (500 mL) within 56 days prior to administration of the study medication.
- •History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day (l Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
- •History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana, pot)within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
- •Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption.
- •Smoking more than 25 cigarettes per day.
- •Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- •Any reason which, in the opinion of the medical sub investigator, would prevent the subject from participating in the study.
研究组 & 干预措施
Tizanidine HCl 4 mg
Experimental
Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
干预措施: Tizanidine (Drug)
Zanaflex
Active Comparator
Zanaflex 4 mg Tablets
干预措施: Tizanidine (Drug)
结局指标
主要结局
Bioequivalence based on Cmax and AUC parameters
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed ConditionsHealthyNCT01065987Dr. Reddy's Laboratories Limited24
已完成
1 期
Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed ConditionHealthyNCT01053689Dr. Reddy's Laboratories Limited44
已完成
1 期
Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting ConditionHealthyNCT01052909Dr. Reddy's Laboratories Limited44
已完成
不适用
Clinical Study on the Bioequivalence of Vitamin D in Healthy AdultsBioequivalence of Vitamin D in Healthy AdultsNCT03552666Church & Dwight Company, Inc.9
已完成
1 期
Bioequivalence Study for Acarbose/Metformin FDCDiabetes Mellitus, Type 2NCT04065581Bayer24